HCV genotypes and their determinative role in hepatitis C treatment
- 4 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in VirusDisease
- Vol. 31 (3), 235-240
- https://doi.org/10.1007/s13337-020-00592-0
Abstract
Nowadays, exposure to infectious diseases caused by pathogenic viruses has become one of the major human concerns in health fields. In the meantime, hepatitis viruses are associated with health problems, especially in liver tissue. So far, several types of these viruses have been known including: HAV, HBV, HCV, HDV, HEV, and HGV. Nevertheless, it seems that hepatitis C is the major viral infection among all of the hepatitis infections. The cirrhosis and hepatocellular carcinoma are known as the most important pathological complications of this virus, from which seven genotypes have been identified. However, among these genotypes, the incidence rate of genotypes 1 and 3 is more than others. In this review, we have investigated the relationship between all HCV genotypes and therapeutic responses against them. Regarding heterogeneity between hepatitis C genotypes, it is not possible to access an effective vaccine against this virus, and treatment is the only applicable strategy. Response to treatment is different among genotypes, and it has resulted that each genotype has a specific therapeutic regimen of itself. Therefore, it seems that determination of hepatitis C genotype, as a key tool, is essential in controlling therapeutic regimen, improving local control programs and eventually producing an effective vaccine.Keywords
This publication has 40 references indexed in Scilit:
- Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus InfectionPLOS ONE, 2013
- Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis CBMC Medicine, 2013
- Interferon-λ in HCV Infection and Therapy
Viruses, 2010
- Virus–host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategiesTrends in Molecular Medicine, 2010
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapyNature Genetics, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and RibavirinThe Journal of Infectious Diseases, 2008
- Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?World Journal of Gastroenterology, 2008
- Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infectionTranslational Research, 2007